Peer-reviewed veterinary case report
Intratumoral hyaluronan-cisplatin injection in dogs with soft tissue
By Venable, Rachel O et al.·Published in American journal of veterinary research·2012·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas.
- Species:
- dog
Plain-English summary
Five dogs with soft tissue sarcomas (a type of cancer) received an injection of a special treatment combining hyaluronan and cisplatin directly into their tumors. This method aimed to deliver a higher concentration of the medication right where it was needed while minimizing side effects. After the treatment, the dogs showed no adverse reactions, and the levels of the drug in the tumors were significantly higher than in their blood. This suggests that the treatment was effective and well-tolerated, offering a promising option for managing this type of cancer in dogs.
People also search for: dog soft tissue sarcoma treatment · cisplatin for dogs cancer · hyaluronan injection for tumors in dogs
Abstract
OBJECTIVE: To determine the effects of intratumoral injection of a hyaluronan-cisplatin nanoconjugate on local and systemic platinum concentrations and systemic toxicosis. ANIMALS: 5 dogs with spontaneous soft tissue sarcomas (STSs). PROCEDURES: For each dog, approximately 1.5 mL of hyaluronan nanocarrier conjugated with 20 mg of cisplatin was injected into an external STS. Blood samples were collected immediately before (0 hours) and at 0.5, 1, 2, 3, 4, 24, and 96 hours after hyaluronan-cisplatin injection for pharmacokinetic analyses. Urine samples were obtained at 0 and at 96 hours after hyaluronan-cisplatin injection for urinalysis. Each treated STS and its sentinel lymph nodes were surgically removed 96 hours after the hyaluronan-cisplatin injection. Inductively coupled plasma mass spectrometry was used to measure platinum concentrations in blood samples, tumors, and lymph nodes. RESULTS: No tissue reactions were detected 96 hours after hyaluronan-cisplatin injection. Mean ± SD area under the curve, peak concentration, and terminal half-life for unbound (plasma) and total (serum) platinum were 774.6 ± 221.1 ng•h/mL and 3,562.1 ± 2,031.1 ng•h/mL, 56.5 ± 20.9 ng/mL and 81.6 ± 40.4 ng/mL, and 33.6 ± 16.1 hours and 51.2 ± 29.1 hours, respectively. Platinum concentrations ranged from 3,325 to 8,229 ng/g in STSs and 130 to 6,066 ng/g in STS-associated lymph nodes. CONCLUSIONS AND CLINICAL RELEVANCE: Intratumoral injection of the hyaluronan-cisplatin nanoconjugate was well tolerated in treated dogs. Following intratumoral hyaluronan-cisplatin injection, platinum concentration was 1,000-fold and 100-fold greater within treated tumors and tumor-draining lymphatics, respectively, compared with that in plasma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/23176425/